Tagworks Pharmaceuticals

Tagworks Pharmaceuticals is a precision therapy company, leveraging its technology platform to develop a new standard of care for patients suffering from severe diseases including cancer. Founded in 2011 and headquartered in The Netherlands, Tagworks is pioneering the Click-to-Release approach, protected by a broad patent estate. The company is focused on developing a pipeline of click-cleavable therapies, with its lead program, TGW101, being an antibody-drug conjugate (ADC) targeting TAG72, a clinically-validated, pan-carcinoma target. This target has remained out of reach of current ADC therapies until now. Tagworks’ technology enables on-target activation of ADCs and immunomodulators, as well as off-target deactivation of radioimmunotherapies to enhance their therapeutic index. The company recently secured a significant $65.00M Series A investment on 22 June 2023, from a notable group of investors, including New Enterprise Associates, Lightstone Ventures, Novartis Venture Fund, Gilde Healthcare, Oost, Ysios Capital, and Meneldor. With its commitment to developing more effective and safer systemic therapies, Tagworks Pharmaceuticals is well-positioned to make a significant impact in the biotechnology, healthcare, and pharmaceutical industries.